



#3 51
8/10/00
GP/1646

LAW OFFICES OF
SYNNESTVEDT & LECHNER LLP
2600 ARAMARK TOWER
1101 MARKET STREET
PHILADELPHIA, PA 19107-2950
TELEPHONE (215) 923-4466
FACSIMILE (215) 923-2189
E-MAIL synnlech@synnlech.com
www.synnlech.com

July 14, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re/ Application of Michael Jaye,
Kim-Anh Thi Doan, John A. Krawiec,
Kevin J. Lynch, Dilip V. Amin,
Victoria J. South, Dawn Marchandier,
Curille Maugeais and Daniel J. Rader
Application No. 09/277,401
Filed March 26, 1999

Art Unit 1646

RECEIVED
JUL 21 2000
RECEIVED CENTER 1600/2900

Compositions and Methods for Effecting the Levels of High-Density
Lipoprotein (HDL) Cholesterol and Apolipoprotein AI, Very Low
Density-Lipoprotein (VLDL) Cholesterol and Low-Density Lipoprotein
(LDL) Cholesterol

(Attorney Docket No. P 22,944-C USA)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on Friday, July 14, 2000.

Marge L. Iaconelli
Marge L. Iaconelli

Assistant Commissioner for Patents
Washington, DC 20231



Sir:

**SUBMISSION OF INFORMATION
DISCLOSURE STATEMENT PURSUANT TO 37 CFR §1.97(b)**

Pursuant to 37 CFR §1.97(b), enclosed herewith is "Form PTO-1449 Modified". The status of the present application is that applicant is awaiting a first Action on the merits.

Summary of the Invention

The invention relates to a composition which is effective in increasing the level of high-density lipoprotein (HDL) cholesterol and apolipoprotein AI in a patient. Increasing the level of HDL cholesterol and apolipoprotein AI is accomplished by lowering the expression of the gene, LIPG, which encodes a lipase enzyme, or by inhibiting the activity of the LIPG lipase enzyme. The invention relates also to a composition which is effective in lowering the levels of very low-density lipoprotein (VLDL) cholesterol and low-density lipoprotein (LDL) cholesterol in a patient. Lowering the levels of VLDL cholesterol and LDL cholesterol is accomplished by increasing the expression of LIPG or enhancing the activity of the LIPG lipase enzyme.

The Publications

Documents AA to AL on sheet 5, AA to AJ on sheet 6, and AA to AD on sheet 7 relate to lipase enzymes.

Documents AE to AL on sheet 7 and AA on sheet 8 relate to high-density lipoprotein (HDL) cholesterol levels and their relation to atherosclerotic diseases.

Documents AB to AG on sheet 8 relate to very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol levels and their relation to atherosclerotic diseases.

Documents AH to AL on sheet 8 and AA to AJ on sheet 9 relate to the role of triacylglycerol lipases in atherosclerotic diseases.

Documents AL on sheet 1, AK on sheet 9 and AA to AB on sheet 10 relate to LIPG lipase enzyme.

Documents AA to AB and AM on sheet 1, AC to AJ on sheet 10, and AA to AI on sheet 11 relate to promoters and enhancers which may be used in the present invention.

Documents AJ to AL on sheet 11 relate to cDNA and mRNA sequences.

Documents AC to AE and AN to AR on sheet 1, AC to AD and AL to AQ on sheet 2, and AA to AI on sheet 12 relate to viral vector systems.

Documents AR on sheet 2 and AL on sheet 3 relate to antisense nucleic acids.

Documents AF on sheet 1, AM on sheet 3, AL on sheet 4, AJ to AL on sheet 12, AA to AJ on sheet 13, AA to AK on sheet 14, and AA on sheet 15 relate to ribozymes.

Documents AG to AJ on sheet 1, AA and AE to AG on sheet 2, AN to AO on sheet 3, and AB to AK on sheet 15 relate to non-viral delivery systems.

Documents AL on sheet 15 and AA on sheet 16 relate to antibodies.

Documents AB to AD on sheet 16 relate to methods of identifying and utilizing inhibitory molecules and enhancer molecules.

Documents AN to AP on sheet 4 relate to the use of intracellular binding proteins to down-regulate gene expression.

Document AB on sheet 2 relates to the administration of apolipoprotein AI to a patient.

Documents AE to AH on sheet 16 relate to the use of LIPG lipase enzyme for treating patients with intrahepatic cholestasis.

Documents AI to AL on sheet 16 and AA to AD on sheet 17 relate to methods for synthesizing cDNA.

RECEIVED
JUL 21 2000
TECH CENTER 1600/2300

Documents AE to AH on sheet 17 relate to methods for localizing the LIPG gene and cloning the LIPG gene.


Documents AI to AL on sheet 17 and AA to AF on sheet 18 relate to methods for measuring LIPG expression in cells.

Document AG to AI on sheet 18 relates to the use of transgenic mice to study LIPG.

Document AC on sheet 2 is an English-language equivalent of WO 94/26914. Document AD on sheet 2 is an English-language equivalent of WO 94/28152. Document AE on sheet 2 is an English-language equivalent of WO 95/18863. Document AF on sheet 2 is an English-language equivalent of WO 95/21931. Document AG on sheet 2 is an English-language equivalent of WO 96/25508. Document AN on sheet 3 is an English-language equivalent of WO 96/17823.

There are no available English-language equivalents for Document AP on sheet 1 and Document AN on sheet 4. Document AP on sheet 1 relates to methods for preparing a replication-defective adenovirus for use as a viral vector. An English-language abstract has been provided for Document AN on sheet 4.

Respectfully submitted,



Gene J. Yao, Esq.
Registration No. P-47,193

SYNNESTVEDT & LECHNER LLP
Suite 2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107
(215) 923-4466

M:\GYao\22,944-C USA\Application\IDS Transmittal Cover.6.wpd